Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Forgacs

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Inflammatory Bowel Diseases|June 20, 2007
Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammationGuy Chung-Faye, Bu'hussain Hayee, Susan Maestranzi, et al.
BMJ (Clinical Research Ed.)|August 13, 2015
Use of faecal occult blood tests in symptomatic patientsRobert Steele, Ian Forgacs, Gwyn McCreanor, et al.
Inflammatory Bowel Diseases|June 4, 2008
Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapseLaurence Maiden, Ken Takeuchi, Rosie Baur, et al.
Clinical Neuropharmacology|July 24, 2012
Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effectsPrashanth Reddy, Pablo Martinez-Martin, Alexandra Rizos, et al.
Health and Quality of Life Outcomes|January 28, 2014
Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD)Prashanth Reddy, Pablo Martinez-Martin, Richard G Brown, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 9, 2009
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of lifeHolger Honig, Angelo Antonini, Pablo Martinez-Martin, et al.
Frontline Gastroenterology|February 28, 2018
Conference report: improving outcomes for gastrointestinal cancer in the UKIan Forgacs, Rachel Ashton, William Allum, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Inflammatory Bowel Diseases|June 20, 2007
Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammationGuy Chung-Faye, Bu'hussain Hayee, Susan Maestranzi, et al.
BMJ (Clinical Research Ed.)|August 13, 2015
Use of faecal occult blood tests in symptomatic patientsRobert Steele, Ian Forgacs, Gwyn McCreanor, et al.
Inflammatory Bowel Diseases|June 4, 2008
Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapseLaurence Maiden, Ken Takeuchi, Rosie Baur, et al.
Clinical Neuropharmacology|July 24, 2012
Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effectsPrashanth Reddy, Pablo Martinez-Martin, Alexandra Rizos, et al.
Health and Quality of Life Outcomes|January 28, 2014
Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD)Prashanth Reddy, Pablo Martinez-Martin, Richard G Brown, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 9, 2009
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of lifeHolger Honig, Angelo Antonini, Pablo Martinez-Martin, et al.
Frontline Gastroenterology|February 28, 2018
Conference report: improving outcomes for gastrointestinal cancer in the UKIan Forgacs, Rachel Ashton, William Allum, et al.
Pageof 2